Currently, several emerging therapies, such as retifanlimab, BMX-001, LCB84, KEYTRUDA (pembrolizumab), and others, are being evaluated in late-stage and mid-stage clinical trials. The successful launch of these potential therapies is likely to bring a positive shift in the treatment paradigm of anal cancer during the forecast period (2024–2034). LAS VEGAS , May 29, 2024 /PRNewswire/ -- DelveInsight's Anal Cancer Market Insights report includes a comprehensive understanding of current treatment practices, anal cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ) and the United Kingdom , and Japan ].
Key Takeaways from the Anal Cancer Market Report According to DelveInsight's analysis, the market size for anal cancer reached ~ USD 7 million in 2023 in the US. As per the assessment done by DelveInsight, the total incident cases of anal cancer in the 7MM were ~20K in 2023, which is likely to increase by 2034 at a CAGR of 2.4% during the study period (2020–2034).
Leading anal cancer companies such as Incyte Corporation, BioMimetix , and others are developing novel anal cancer drugs that can be available in the anal cancer market in the coming years. The promising anal cancer therapies in the pipeline include Retifanlimab, BMX-001 , and others. The launch of the retifanlimab is expected to transform the treatment landscape, .
